Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
31 Março 2021 - 6:38AM
Dow Jones News
By Cecilia Butini
Shares in French biopharmaceutical group Ipsen rose on Wednesday
after the company said the European Commission has given the green
light to the company's drug Cabometyx in combination with Bristol
Myers Squibb Co.'s Opdivo for the treatment of renal cell
carcinoma, a type of kidney cancer.
At 0900 GMT, Ipsen shares traded 4.4% higher at EUR73.05.
The company said the EU approval is based on results from a
phase-3 trial named CheckMate-9ER, whose primary endpoint was the
median progression-free survival in patients receiving the drug
combination.
Progression-free survival--which is understood as the time after
treatment that a patient can live without the disease
worsening--was observed as doubling in patients receiving the drug
combination compared with those receiving another, previously
approved drug.
EU approval means the drug combination can be marketed for renal
cell carcinoma in EU member states, Norway, Liechtenstein and
Iceland, while the U.S. already granted approval in January, Ipsen
said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 31, 2021 05:23 ET (09:23 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024